Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
February 08, 2021 07:36 ET
|
Repligen Corporation
WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo...
Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 13:00 ET
|
Repligen Corporation
WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Option
December 10, 2020 16:18 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725...
Repligen Corporation Prices Public Offering of Shares of Common Stock
December 07, 2020 21:41 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a...
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
December 07, 2020 07:22 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock....
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
November 05, 2020 07:30 ET
|
Repligen Corporation
Reports record quarterly revenue of $94.1 million with strong margin expansionOverall revenue grew 35% year-over-year, with organic growth of 31% Raises revenue guidance to $348-$352 million and...
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
October 27, 2020 16:15 ET
|
Repligen Corporation
Proposed ARTeSYN acquisition adds gold standard single-use downstream bioprocessing systemsAdvances Repligen’s Systems strategy in Filtration and Chromatography, complementing TangenX® Flat Sheet...
Repligen to Report Third Quarter 2020 Financial Results
October 22, 2020 07:30 ET
|
Repligen Corporation
- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST - WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that...
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
October 01, 2020 06:30 ET
|
Repligen Corporation
WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo...
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
July 30, 2020 07:30 ET
|
Repligen Corporation
Reports record quarterly revenue of $87.5 millionOverall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing...